|
|
Blood, 15 October 2004, Vol. 104, No. 8, pp. 2505-2513.
Prepublished online as a Blood First Edition Paper on June 29, 2004; DOI 10.1182/blood-2004-02-0483.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences
Hui Liu,
Jin Wang, and
Elliot M. Epner
From the Department of Medicine, University of Arizona School of Medicine and Arizona Cancer Center, Tucson; and Department of Molecular and Cellular Biology, University of Arizona, Tucson.
Cyclin D1 expression is deregulated by chromosome translocation in mantle cell lymphoma and a subset of multiple myeloma. The molecular mechanisms involved in long-distance gene deregulation remain obscure, although changes in acetylated histones and methylated CpG dinucleotides may be important. The patterns of DNA methylation and histone acetylation were determined at the cyclin D1 locus on chromosome 11q13 in B-cell malignancies. The cyclin D1 promoter was hypomethylated and hyperacetylated in expressing cell lines and patient samples, and methylated and hypoacetylated in nonexpressing cell lines. Domains of hyperacetylated histones and hypomethylated DNA extended over 120 kb upstream of the cyclin D1 gene. Interestingly, hypomethylated DNA and hyperacetylated histones were also located at the cyclin D1 promoter but not the upstream major translocation cluster region in cyclin D1-nonexpressing, nontumorigenic B and T cells. RNA polymerase II binding was demonstrated both at the cyclin D1 promoter and 3' immunoglobulin heavy-chain regulatory regions only in malignant B-cell lines with deregulated cyclin D1 expression. Our results suggest a model where RNA polymerase II bound at IgH regulatory sequences can activate the cyclin D1 promoter by either long-range polymerase transfer or tracking.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C.-H. Su, Y.-J. Shann, and M.-T. Hsu
p53 Chromatin Epigenetic Domain Organization and p53 Transcription
Mol. Cell. Biol.,
January 1, 2009;
29(1):
93 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Liu, J. Huang, J. Wang, S. Jiang, A. S. Bailey, D. C. Goldman, M. Welcker, V. Bedell, M. L. Slovak, B. Clurman, et al.
Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma
J. Exp. Med.,
August 4, 2008;
205(8):
1843 - 1858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Ford, L. Shen, Y. C. Lin-Lee, L. V. Pham, A. Multani, H.-J. Zhou, A. T. Tamayo, C. Zhang, L. Hawthorn, J. K. Cowell, et al.
Development of a murine model for blastoid variant mantle-cell lymphoma
Blood,
June 1, 2007;
109(11):
4899 - 4906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Shi, J. Guo, D. J. Duff, F. Rahmatpanah, R. Chitima-Matsiga, M. Al-Kuhlani, K. H. Taylor, O. Sjahputera, M. Andreski, J. E. Wooldridge, et al.
Discovery of novel epigenetic markers in non-Hodgkin's lymphoma
Carcinogenesis,
January 1, 2007;
28(1):
60 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Lacrima, A. Valentini, C. Lambertini, M. Taborelli, A. Rinaldi, E. Zucca, C. Catapano, F. Cavalli, A. Gianella-Borradori, D. E. MacCallum, et al.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
Ann. Onc.,
July 1, 2005;
16(7):
1169 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wang, H. Liu, C. M. Lin, M. I. Aladjem, and E. M. Epner
Targeted Deletion of the Chicken {beta}-Globin Regulatory Elements Reveals a Cooperative Gene Silencing Activity
J. Biol. Chem.,
June 17, 2005;
280(24):
23340 - 23348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
